Recently, in a recent phase II study 125 patients with metastatic pancreatic cancer were treated with 1500 mg of Lapatinib per day and 1g m−2 per week of gemcitabine for 3 weeks until the disease progression.
In a recent phase I study of PulmoBind, qualitative analysis of lung scans by experienced nuclear specialist revealed that PulmoBind imaging quality was superior to that historically obtained with MAA.
In a recent phase 2 clinical study, an allogeneic PCa whole-cell vaccine stimulated expansion of tumor-specific immune cells in non-metastatic androgen-independent PCa patients [10].
In a recent phase II clinical trial, patients with PTLD showed better responses when the infused T cell preparations contained higher numbers of CD4+ T cells [18].
Pharmacologic vitamin C concentrations produced in animals by parenteral administration were reproduced in patients in a recent phase I clinical trial [16].
A vaccine based on a recombinant circumsporozoite protein, RTS,S was shown in a recent phase 2 clinical trial in 5 17 month old children to have 53% vaccine efficacy against P. falciparum malaria clinical episodes.
A Plasmodium falciparum 3D7 strain Apical Membrane Antigen-1 (AMA1) vaccine, formulated with AS02A adjuvant, slowed parasite growth in a recent Phase 1/2a trial, however sterile protection was not observed.
However, in a recent phase IIa clinical trial, vabicaserin demonstrated only moderate efficacy in schizophrenia as monotherapy.
97 In a recent phase II trial, erlotinib and carboplatin combination therapy was more active in sensitive than -resistant disease.
Increased hematologic toxicities have been reported in a recent phase I study of combination therapy involving gefitinib and vinorelbine [ 16].
26 Vinorelbine, an antimicrotubule agent, has demonstrated a response rate of 21% in a recent phase II trial.
